Key facts
- This page summarizes Jonathan E. Freeman's Form 4 filing for Phio Pharmaceuticals Corp. (PHIO).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 13 Sep 2024, 14:59.
Jonathan E. Freeman - 11 Sep 2024 Form 4 Insider Report for Phio Pharmaceuticals Corp. (PHIO)
- Reporting relationship
- Director
- Issuer ticker
- PHIO
- Reported as of
- 11 Sep 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 13 Sep 2024, 14:59:52 UTC
- Prior SEC filing
- 22 Feb 2023
- Next SEC filing
- 15 Sep 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Robert M. Infarinato, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jonathan E. Freeman filed Form 4 for Phio Pharmaceuticals Corp. (PHIO) on 13 Sep 2024.
Change
- Previous filing in this sequence was filed on 22 Feb 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PHIO
transaction
Common Stock, $0.0001 par value
Award
- Transaction value
- $0
- Shares
- +1,000
- Change %
- Price
- $0.000000
- Shares after
- 1,000
- Date
- 11 Sep 2024
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents shares underlying a restricted stock unit, which shares will vest on the first anniversary of the grant.
Footnote F2
Includes shares of common stock underlying unvested restricted stock units.